[12] Patent
[11] Patent No.:GC0011493  
[45] Date of Publishing the Grant of the Patent: 30/Nov /2020                76/2020  
Number of the Decision to Grant the Patent:2020/174766
Date of the Decision to Grant the Patent:11/Nov/2020

[21] Application No.:GCC/P/2005/19676

[22] Filing Date:9/1/2005

[30] Priority:

[33] State [32] Priority date [31] Priority No.

[72] Inventors:1- Nicholas Pullen،2- Elizabeth Molloy،3- Sirid-Aimée Kellermann،4- Larry L. Green،5- Mary Haak – Frendscho

[73] Owners:1- Amgen Fremont Inc., 6701 Kaiser Drive, California, USA،2- PFIZER INC., USA

[74] Agent: Suleiman I. Al-Ammar Law Office





[56] Cited Documents:

-US 2001/0046490 A1 (DRE I MAN ef al.) 29 November 2001
-US 2002/0065220 A1 (YOUNG et al.) 30 May 2002
Examiner: Ashwaq Hamed Al-Ghanami

[57] Abstract: [0284] The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that specifically bind to MAdCAM, preferably human MAdCAM and that function to inhibit MAdCAM. The invention also relates to human anti-MAdCAM antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-MAdCAM antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-MAdCAM antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-MAdCAM antibodies. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the invention.
No. of claims: 39     No. of figures: 7


Note: Any interested individual may, within 3 months of publication of the grant, file objection thereof with the Grievance Committee after payment of grievance fees.